RenovoRx Completes Enrollment in Phase III Pancreatic Cancer Trial
Event summary
- RenovoRx completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer (LAPC) on August 7, 2026.
- The trial aims to evaluate the efficacy of intra-arterial gemcitabine (IAG) via RenovoCath compared to standard systemic chemotherapy.
- Topline data readout is expected in the second half of 2027, following trial completion in the first half of 2027.
The big picture
RenovoRx's completion of the TIGeR-PaC trial enrollment marks a critical step in validating its Trans-Arterial Micro-Perfusion (TAMP) platform for targeted chemotherapy delivery. The trial's success could set a new standard for treating locally advanced pancreatic cancer, an area with significant unmet medical needs and limited therapeutic progress. The strategic adaptability of the RenovoCath device to integrate with evolving systemic therapies positions RenovoRx as a key player in the oncology space.
What we're watching
- Clinical Efficacy
- Whether the TIGeR-PaC trial will demonstrate superior overall survival for IAG compared to standard systemic chemotherapy.
- Regulatory Pathway
- The pace at which RenovoRx can secure FDA approval for IAG, given the Orphan Drug Designation and positive interim analyses.
- Commercialization Strategy
- How RenovoRx will scale commercial efforts for RenovoCath while advancing its drug-device combination product pipeline.
Related topics